NewsEuropeSuppliers Selected For Ireland’s Medical Cannabis Pilot

Suppliers Selected For Ireland’s Medical Cannabis Pilot

-

TWO companies have been approved as the first suppliers to Ireland’s recently launched medical cannabis programme.

The Irish Government signed off on the launch of its five-year pilot in June, with Canadian firm Aurora and MGC Pharmaceuticals, of Australia, selected to provide its first cannabis medicine.

Under the scheme consultants can prescribe to patients for spasticity, associated with multiple sclerosis, chemotherapy-related intractable nausea and treatment-resistant epilepsy.

The two products are Aurora High CBD Oil Drops and CannEpil, both are CBD based drugs with the latter being used to treat epilepsy.

However, much like its UK neighbour there will be a time-lag of weeks between prescription and receipt of the drug.

The Irish Journal reports that under the scheme the two companies have to apply for a licence to bring the product into Ireland for distribution. 

CannEpil is a product that ‘has been years in the making’, and was released into the market in 2017, says Roby Zomer, Executive Director and CEO at MGC. 

The Medical Cannabis Access Programme was signed into law in June this year, by Ireland’s Minister for Health, Simon Harris. 

Mr Harris said at the time that the programme would allow ‘compassionate access to cannabis for medical reasons’ in cases where conventional treatment has failed.

The Irish Government says it wants to encourage the development of a home-grown cannabis cultivation and hemp industry saying it the potential to create over 80,000 jobs.


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial

AFTER launching a patient registry earlier this year further signs the UK’s National Health Service is warming to cannabis...

Reakiro – Europe’s Leading CBD And Hemp Brand – Delivers The Complete B2B & B2C Package

IN a time when CBD products are becoming unavoidable in the health, wellness and fitness industries, it is more...

Is Luxembourg’s Quest To Introduce An Adult-Use Cannabis Programme Going Up In Smoke?

CONCERNS over Luxembourg’s intent to become the first European country to legalise adult-use cannabis have emerged. In an interview on...

Cannabis Is Now A Compelling Opportunity For The Main Tobacco Companies

International cannabis expert, Barbara Pastori, of Prohibition Partners shares her thoughts on why cannabis is a compelling opportunity for...

Oxford Cannabinoid Technologies Holdings Sign Exclusive Worldwide License Agreement With Canopy Growth

Oxford Cannabinoid Technologies Holdings plc (OCTP), the holding company of Oxford Cannabinoid Technologies Ltd (“OCT”) (together, the “Group”), a...

With Global Cannabis Cultivation Capacity Set To Outstrip Demand One Hundredfold – What Happened To The ‘Green’ Rush?

CANNABIS investors need to be wary when it comes to cultivation, says Oliver Zugel, Founder and CEO FoliuMed Holdings. Where...

Must read

Plans Unveiled For First National Health Service-Backed Medical Cannabis Clinical Trial

AFTER launching a patient registry earlier this year further...

Is Luxembourg’s Quest To Introduce An Adult-Use Cannabis Programme Going Up In Smoke?

CONCERNS over Luxembourg’s intent to become the first European...

You might also likeRELATED
Recommended to you